Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2021

View Archived Issues

Proof-of-concept study of two targeted phage-based vaccination approaches against SARS-CoV-2

Dizal (Jiangsu) Pharmaceutical discovers Bruton tyrosine kinase inhibitors

New DNA-dependent protein kinase inhibitors identified at Chengdu Baiyu Pharmaceutical

LegoChem Biosciences descibes new antibody-drug conjugates

Reyoung divulges new autophagy inhibitors

180 Life Sciences selects lead synthetic CBD analogue for inflammation and pain

MindMed begins phase I study of DMT

New SERD discovered by dynamics simulation shows promise for breast cancer therapy

COVIDITY-001 study of SCOV-1 and SCOV-2 vaccine candidates approved in South Africa

Vaxart's oral norovirus vaccine boosts immune responses in previously vaccinated subjects

Initial data reported from phase Ib study of ATRC-101

AUG-3387 binds and neutralizes the SARS-CoV-2 Delta variant in vitro

KV-998083 effective in models of thrombosis and vascular leakage

Positive phase II data for LB-1148 in patients undergoing gastrointestinal surgery

In vivo gene editing alleviates amyloid pathologies

FDA clears IND application for DCR-AUD

Enrollment opens in phase IIa study of MT-3921 for acute traumatic cervical spinal cord injury

S2X259, novel human MAb with potential to overcome the emergence of SARS-CoV-2 variants

Eli Lilly presents SAD and MAD data for LY-3372689 in healthy volunteers

JNJ-78278343 enters phase I trial for advanced prostate cancer

TVB-2640 shows promising efficacy in phase II FASCINATE-1 study in patients with NASH

HA-121-28 studied in phase II for medullary thyroid carcinoma

SymBio opens phase IIa study of brincidofovir in subjects with adenovirus infection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...